title: Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
abstract: The prognostic significance of p53 mutation, microsattelite instability and DNA mismatch protein hMLH1 expression in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin was evaluated. The overall combination chemotherapy response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than those with wild-type p53 tumors (35/42 (83%) vs. 32/58 (55%); P=0.003 and 18/42 (43%) vs. 16/58 (28%); P=0.03, respectively). This tendency apparently existed in non-serous carcinoma, but not in serous carcinoma. Univariate analysis showed that the risk of death due to disease and risk of progression was significantly lower among patients with p53 mutation (P=0.0357 and 0.0281, respectively). However, the presence of microsattelite instability or loss of hMLH1 expression was not associated with either the clinical response or prognosis. Determining p53 mutational status can be useful in predicting therapeutic response to drugs in ovarian carcinoma, especially in non-serous tumors.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka University Faculty of Medicine, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ueno
authors.forename: Takayuki
authors.initials: T
authors.lastname: Enomoto
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Otsuki
authors.forename: Nagatoshi
authors.initials: N
authors.lastname: Sugita
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Nakashima
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshino
authors.forename: Chie
authors.initials: C
authors.lastname: Kuragaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ueda
authors.forename: Tadaatsu
authors.initials: T
authors.lastname: Aki
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Ikegami
authors.forename: Masato
authors.initials: M
authors.lastname: Yamazaki
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Ito
authors.forename: Masaaki
authors.initials: M
authors.lastname: Nagamatsu
authors.forename: Takamichi
authors.initials: T
authors.lastname: Nishizaki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asada
authors.forename: Takashi
authors.initials: T
authors.lastname: Kameda
authors.forename: Akinori
authors.initials: A
authors.lastname: Wakimoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Mizutani
authors.forename: Takako
authors.initials: T
authors.lastname: Yamada
authors.forename: Yuji
authors.initials: Y
authors.lastname: Murata
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000235:genetics / Q000601:surgery; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D018895:Microsatellite Repeats / Q000187:drug effects / Q000235:genetics; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D016190:Carboplatin; D017239:Paclitaxel